Immunotherapy in head and neck cancer

被引:0
|
作者
Kansy, B. [1 ]
Hussain, T. [1 ]
Mattheis, S. [1 ]
Wollenberg, B. [2 ]
Brandau, S. [1 ]
Lang, S. [1 ]
机构
[1] Univ Duisburg Essen, Univ Klinikum Essen, Klin Hals Nasen Ohrenheilkunde Kopf & Hals Chirur, D-45147 Essen, Germany
[2] Univ Klinikum Schleswig Holstein, Klin & Poliklin Hals Nasen & Ohrenheilkunde, D-23538 Lubeck, Germany
关键词
Monoclonal antibodies; Interleukins; Tumor escape; Checkpoint receptors; Antigens; CD28; CD80; SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CANCER; PROGNOSTIC VALUE; MELANOMA; VACCINE; TUMOR;
D O I
10.1007/s00106-015-0076-8
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The physiological immune response to malignant cells is based on the interaction of antigen-presenting cells, such as dendritic cells and macrophages, with T and B lymphocytes. CD8(+) effector and natural killer cells are primarily responsible for tumor cell lysis. Tumor cells exploit several mechanisms to influence the body's immune system and promote development and progress of solid head and neck malignancies. Via regulatory T cells, myeloid-derived suppressor cells, tumor-associated macrophages, and cancer-associated fibroblasts, tumor cells promote development of suppressive signaling pathways that enable tumor progression. Novel immune therapeutics aim to influence these signaling pathways. Current studies are investigating agents which influence immune-stimulating or immune-suppressive cytokines, as well as drug-based Toll-like receptor activation and vaccination in head and neck cancer. Development of monoclonal antibodies allows for direct and highly specific binding of therapeutics to cell receptors recently discovered immune checkpoint receptors are particularly intriguing targets. Monoclonal antibodies directed specifically toward T cell-stimulating receptors such as CD28 and CD134, or immunosuppressive receptors CTLA-4 and PD-1, are currently under investigation and have shown promising results.
引用
收藏
页码:797 / 803
页数:7
相关论文
共 50 条
  • [21] Head and Neck Cancer Immunotherapy: Clinical Evaluation
    Leibowitz, Michael S.
    Nayak, Jayakar V.
    Ferris, Robert L.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (02) : 162 - 169
  • [22] Biomarkers for immunotherapy response in head and neck cancer
    Gavrielatou, Niki
    Doumas, Stergios
    Economopoulou, Panagiota
    Foukas, Periklis G.
    Psyrri, Amanda
    CANCER TREATMENT REVIEWS, 2020, 84
  • [23] Immunotherapy in Head and Neck Squamous Cell Cancer
    Denaro, Nerina
    Merlano, Marco Carlo
    CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY, 2018, 11 (04) : 217 - 223
  • [24] The evolving role of immunotherapy in head and neck cancer
    Tahara, Makoto
    ANNALS OF ONCOLOGY, 2015, 26 : 33 - 33
  • [25] Immunotherapy in head and neck cancer: a new paradigm
    Reverdy, Thibaut
    Karabakakian, Andy
    Gau, Max
    Fayette, Jerome
    ANTI-CANCER DRUGS, 2018, 29 (05) : 385 - 386
  • [26] Patient selection for immunotherapy in head and neck cancer
    Bonomo, Pierluigi
    Orlandi, Ester
    Bossi, Paolo
    LANCET ONCOLOGY, 2021, 22 (07): : E290 - E290
  • [27] Immunotherapy in head and neck cancer: evidence and perspectives
    Tosoni, Alicia
    Franceschi, Enrico
    Pasquini, Ernesto
    Lanese, Andrea
    Donini, Elisa
    Foschini, Maria Pia
    Dall'Olio, Danilo
    Brandes, Alba A.
    IMMUNOTHERAPY, 2017, 9 (16) : 1351 - 1358
  • [28] Immunotherapy for head and neck cancer: advances and deficiencies
    De Costa, Anna-Maria
    Young, M. Rita I.
    ANTI-CANCER DRUGS, 2011, 22 (07) : 674 - 681
  • [29] Immunobiology and immunotherapy of head and neck cancer.
    Whiteside T.L.
    Current Oncology Reports, 2001, 3 (1) : 46 - 55
  • [30] IMMUNOTHERAPY IN PATIENTS WITH HEAD AND NECK-CANCER
    VINZENZ, K
    MICKSCHE, M
    INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1986, 2 (01): : 37 - 49